Amanote Research
Register
Sign In
Prescription Practice of Biological Drugs in Rheumatoid Arthritis During the First 3 Years of Post-Marketing Use in Denmark and Norway: Criteria Are Becoming Less Stringent
Annals of the Rheumatic Diseases
- United Kingdom
doi 10.1136/ard.2004.031252
Full Text
Open PDF
Abstract
Available in
full text
Categories
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Date
August 1, 2005
Authors
E Hjardem
Publisher
BMJ
Related search
Use of Genetically Engineered Biological Drugs for Rheumatoid Arthritis in the Russian Federation
Nauchno-Prakticheskaya Revmatologiya
Rheumatology
Allergy
Immunology
Changes in Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983-2009
Arthritis Care and Research
Rheumatology
Use of Prescription Medication Prior to Suicide in Norway
BMC Health Services Research
Health Policy
Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Increasing Use of Prescription Drugs in the United Kingdom
Pharmacoepidemiology and Drug Safety
Epidemiology
Pharmacology
Acute Poisoning Related to the Recreational Use of Prescription Drugs: An Observational Study From Oslo, Norway
BMC Emergency Medicine
Emergency Medicine
Accuracy of Methotrexate Use in Rheumatoid Arthritis Patients in Emanuel Klampok Hospital Based on Explicit Criteria
Indonesian Journal of Clinical Pharmacy
Are the ‘Resident’ Dolphins of Doubtful Sound Becoming Less Resident?
Endangered Species Research
Landscape Conservation
Ecology
Nature
Prospective Trial Comparing the Use of Sulphasalazine and Auranofin as Second Line Drugs in Patients With Rheumatoid Arthritis.
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
